Modified Delphi panel consensus recommendations for management of severe aplastic anemia

Author:

Babushok Daria V.1,DeZern Amy E.2,de Castro Carlos M.3ORCID,Rogers Zora R.4ORCID,Beenhouwer David5,Broder Michael S.5,Fanning Suzanne R.6,Gibbs Sarah N.5,Hanna Rabi7,Maciejewski Jaroslaw P.8,Scott Bart L.9ORCID,Tantravahi Srinivas K.10,Wlodarski Marcin W.11ORCID,Yermilov Irina5ORCID,Patel Bhumika J.6ORCID

Affiliation:

1. 1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA

2. 2Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

3. 3Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Durham, NC

4. 4Division of Pediatric Hematology-Oncology, University of Texas, Southwestern Medical Center, Dallas, TX

5. 5Partnership for Health Analytic Research, Beverly Hills, CA

6. 6Prisma Health Cancer Institute, University of South Carolina, Greenville, SC

7. 7Department of Pediatric Hematology Oncology and Bone Marrow Transplantation, Cleveland Clinic, Cleveland, OH

8. 8Translational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH

9. 9Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

10. 10Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

11. 11Department of Hematology, St. Jude Children’s Research Hospital, Memphis, TN

Abstract

Abstract Severe aplastic anemia (SAA) is a rare hematologic condition for which there is no clear management algorithm. A panel of 11 experts on adult and pediatric aplastic anemia was assembled and, using the RAND/University of California, Los Angeles modified Delphi panel method, evaluated >600 varying patient care scenarios to develop clinical recommendations for the initial and subsequent management of patients of all ages with SAA. Here, we present the panel’s recommendations to rule out inherited bone marrow failure syndromes, on supportive care before and during first-line therapy, and on first-line (initial management) and second-line (subsequent management) therapy of acquired SAA, focusing on when transplant vs medical therapy is most appropriate. These recommendations represent the consensus of 11 experts informed by published literature and experience. They are intended only as general guidance for experienced clinicians who treat patients with SAA and are in no way intended to supersede individual physician and patient decision making. Current and future research should validate this consensus using clinical data. Once validated, we hope these expert panel recommendations will improve outcomes for patients with SAA.

Publisher

American Society of Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3